Company

AMILI

Microbiome science company running a multi-ethnic Asian gut microbiome biobank and reference database, which it uses to interpret consumer and clinician-ordered stool tests. Commercial output is diagnostic rather than therapeutic: a gut microbiome test kit and an enhanced version, four targeted probiotic formulations (immune-metabolic, complete, cognitive, digestive), microbiome restoration therapy, and AMILI Optimise Plus, a metabolic health programme that pairs microbiome profiling with continuous glucose monitoring and nutritionist input. Distribution runs through a partner clinic network. Longevity relevance is indirect: it sits in the metabolic-health and personalised-nutrition layer, measuring and modifying a biomarker set (gut composition, glycaemic response) associated with cardiometabolic risk, not intervening in ageing biology directly. Efficacy claims for microbiome-guided nutrition remain contested in the literature; the company's own database size claims are self-reported and not independently verified here.

At a glance

Listing: Private, not listed
Category: Diagnostics
Headquarters: Singapore (89 Science Park Drive, #03-09, The Rutherford, Science Park 1)
Market cap: Not disclosed

Thesis

Why it is in this universe

Category: Diagnostics
Market: Singapore
Recent inflection: On 21 April 2026, Calbee launched its Body Granola personalised nutrition service in Singapore with AMILI supplying the gut microbiome testing component, extending AMILI from direct-to-consumer testing into a consumer packaged goods partnership (NutraIngredients, 22 April 2026).
Services: None recorded
People tracked: None on file

Market data

Listing and scale

Metric	Detail
Exchange	Unlisted
Ticker	None
Secondary listing	None
Market cap	Not disclosed
Status	Private

Editor's noteA listing or financing event is not a clinical result. variis grades evidence on the linked protocol, not the share price.

Get in touch

Contact

Address: Singapore (89 Science Park Drive, #03-09, The Rutherford, Science Park 1)
Website: www.amili.asia
Phone: No public number published
Email: No public address published

Offering

What it sells today

No commercial services are recorded for this company yet.

Recent inflection

What moved lately

On 21 April 2026, Calbee launched its Body Granola personalised nutrition service in Singapore with AMILI supplying the gut microbiome testing component, extending AMILI from direct-to-consumer testing into a consumer packaged goods partnership (NutraIngredients, 22 April 2026).

Common questions

Why does variis track AMILI?: Microbiome science company running a multi-ethnic Asian gut microbiome biobank and reference database, which it uses to interpret consumer and clinician-ordered stool tests. Commercial output is diagnostic rather than therapeutic: a gut microbiome test kit and an enhanced version, four targeted probiotic formulations (immune-metabolic, complete, cognitive, digestive), microbiome restoration therapy, and AMILI Optimise Plus, a metabolic health programme that pairs microbiome profiling with continuous glucose monitoring and nutritionist input. Distribution runs through a partner clinic network. Longevity relevance is indirect: it sits in the metabolic-health and personalised-nutrition layer, measuring and modifying a biomarker set (gut composition, glycaemic response) associated with cardiometabolic risk, not intervening in ageing biology directly. Efficacy claims for microbiome-guided nutrition remain contested in the literature; the company's own database size claims are self-reported and not independently verified here.
Is AMILI publicly listed?: variis has no ticker on file for AMILI, so it is tracked as private or unlisted. Absence of a ticker on this record is not a statement that no listing exists anywhere.
Where is AMILI based?: Singapore (89 Science Park Drive, #03-09, The Rutherford, Science Park 1)
Is AMILI still trading?: AMILI is recorded as private.

Keep reading

Related coverage from the newsroom.

Singapore and Australia · Capital

Two rounds, one IPO: how Singapore and Australia are funding longevity in 2025 to 2026

Suggest an update

Sources

What this profile is built on

AMILI: precision gut microbiome company (official site, HQ address and product range) · AMILI
Calbee and gut microbiome firm AMILI bring personalised nutrition to Singapore · NutraIngredients
Singapore redefines longevity through science and policy · Asia Tech Lens

Last updated 14 August 2026

Every entity profile on variis is sourced. Not investment advice.

Metric

Detail

Exchange

Unlisted

Ticker

None

Secondary listing

None

Market cap

Not disclosed

Status

Private

Common questions

Why does variis track AMILI?

Microbiome science company running a multi-ethnic Asian gut microbiome biobank and reference database, which it uses to interpret consumer and clinician-ordered stool tests. Commercial output is diagnostic rather than therapeutic: a gut microbiome test kit and an enhanced version, four targeted probiotic formulations (immune-metabolic, complete, cognitive, digestive), microbiome restoration therapy, and AMILI Optimise Plus, a metabolic health programme that pairs microbiome profiling with continuous glucose monitoring and nutritionist input. Distribution runs through a partner clinic network. Longevity relevance is indirect: it sits in the metabolic-health and personalised-nutrition layer, measuring and modifying a biomarker set (gut composition, glycaemic response) associated with cardiometabolic risk, not intervening in ageing biology directly. Efficacy claims for microbiome-guided nutrition remain contested in the literature; the company's own database size claims are self-reported and not independently verified here.

Is AMILI publicly listed?

variis has no ticker on file for AMILI, so it is tracked as private or unlisted. Absence of a ticker on this record is not a statement that no listing exists anywhere.

Where is AMILI based?

Singapore (89 Science Park Drive, #03-09, The Rutherford, Science Park 1)

Is AMILI still trading?

AMILI is recorded as private.